Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

Thomas Powles, Robert J. Motzer, Bernard Escudier, Sumanta Pal, Christian Kollmannsberger, Joanna Pikiel, Howard Gurney, Sun Young Rha, Se Hoon Park, Poul F. Geertsen, Marine Gross-Goupil, Enrique Grande, Cristina Suarez, David W. Markby, Alan Arroyo, Mark Dean, Toni K. Choueiri, Daniel George

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. Methods: Outcomes were evaluated for subgroups defined by prior therapy with sunitinib or pazopanib as the only prior VEGFR inhibitor, or prior anti-PD-1/PD-L1 therapy. Results: For the prior sunitinib subgroup (N = 267), median PFS for cabozantinib versus everolimus was 9.1 versus 3.7 months (HR 0.43, 95% CI 0.32–0.59), ORR was 16% versus 3%, and median OS was 21.4 versus 16.5 months (HR 0.66, 95% CI 0.47–0.93). For the prior pazopanib subgroup (N = 171), median PFS for cabozantinib versus everolimus was 7.4 versus 5.1 months (HR 0.67, 95% CI 0.45–0.99), ORR was 19% versus 4%, and median OS was 22.0 versus 17.5 months (HR 0.66, 95% CI 0.42–1.04). For prior anti-PD-1/PD-L1 therapy (N = 32), median PFS was not reached for cabozantinib versus 4.1 months for everolimus (HR 0.22, 95% CI 0.07–0.65), ORR was 22% versus 0%, and median OS was not reached versus 16.3 months (HR 0.56, 95% CI 0.21–1.52). Conclusions: Cabozantinib was associated with improved clinical outcomes versus everolimus in patients with advanced RCC, irrespective of prior therapy, including checkpoint inhibitor therapy.

Original languageEnglish
Pages (from-to)663-669
Number of pages7
JournalBritish journal of cancer
Volume119
Issue number6
DOIs
Publication statusPublished - 2018 Sep 11

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Powles, T., Motzer, R. J., Escudier, B., Pal, S., Kollmannsberger, C., Pikiel, J., Gurney, H., Rha, S. Y., Park, S. H., Geertsen, P. F., Gross-Goupil, M., Grande, E., Suarez, C., Markby, D. W., Arroyo, A., Dean, M., Choueiri, T. K., & George, D. (2018). Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British journal of cancer, 119(6), 663-669. https://doi.org/10.1038/s41416-018-0164-0